Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04101370
Other study ID # BOZ-501
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 24, 2018
Est. completion date June 20, 2018

Study information

Verified date March 2019
Source Geropharm
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bioequivalence Study of 2 formulation of bosentan (Bosentan GEROPHARM vers. Tracleer® Actelion)


Description:

Study to evaluate the bioequivalence of orally administered bosentan preparations, immediate release tablets, 125 mg in normal healthy subjects under fasting conditions


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date June 20, 2018
Est. primary completion date June 20, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Signed informed consent form.

- Healthy male aged 18 to 45 years.

- Verified diagnosis is "healthy" according to data Standard clinical, laboratory and Instrumental methods of examination.

- Have a body mass index between 18,5 and 30 kg/m2.

- Subjects must use, with their partner, methods of highly effective contraception throughout the study and 30 days after the end of study.

- Ability to keep fasting state for at least 14 hours.

- Consent and ability to respect the schedule of visits and the points of the Protocol.

Exclusion Criteria:

- History of serious allergic problems/events.

- Medicinal intolerance.

- Any acute and chronic diseases of the cardiovascular system, cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood.

- Psychiatric disorders, history of epilepsy and seizures.

- Acute infectious diseases in less than 4 weeks before the start of the study.

- Subjects who have taken medication 2 weeks preceding before the study.

- Subjects who have taken any drugs known effects on hemodynamics or to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication (examples of inducers: barbiturates, omeprazole, etc.).

- Donation of plasma (450 mL or more) within 2 month prior to administration of the study medication.

- History of significant alcohol or drugs abuse or any indication of the regular use of more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or 50 mL of alcohol 40%).

- Smokers.

- Participation in other clinical training is less than than for 3 months before the study.

- Lack of signed informed consent form.

- 10% deviation from references in lab tests.

- Positive testing for alcohol, drugs.

- Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours before the start of the study.

- Any diet (vegetarian, etc.) extreme physical exercise, night shift work.

- Heart rate below 60 or above 80 beats per minute.

- Systolic blood pressure less than 110 mm Hg or more than 139 mm Hg.

- Diastolic blood pressure less than 60 mm Hg or more than 89 mm Hg.

- Volunteers, for Investigator opinion, who can not understand and evaluate the information about this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bosentan 125 mg
Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
Tracleer 125Mg Tablet
Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition

Locations

Country Name City State
Russian Federation Clinical Hospital ? 3 Yaroslavl

Sponsors (1)

Lead Sponsor Collaborator
Geropharm

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax Pharmacokinetics of bosentan by Assessment of Observed Maximum Plasma Concentration (Cmax) 0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.
Primary AUC(0-t) Pharmacokinetics of bosentan by Assessment of Area Under the Curve From Time Zero Extrapolated to "t" (AUC(0-t)) 0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.
See also
  Status Clinical Trial Phase
Completed NCT03705533 - Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State Phase 1
Completed NCT04938856 - Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions Phase 1
Completed NCT03646331 - Bioequivalence of Imeglimin Tablet Formulations Phase 1
Completed NCT04564456 - A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Phase 1
Completed NCT05197517 - Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition Phase 1
Completed NCT03702894 - Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions Phase 1
Completed NCT03018015 - Ibuprofen Bioavailability Trial With Oral Single Dose Administration. Phase 1
Withdrawn NCT02894515 - Bioequivalence Study of Idalopirdine in Healthy Subjects Phase 1
Completed NCT02206295 - Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg Phase 1
Completed NCT01331993 - A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation Phase 1
Completed NCT01260805 - A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers. Phase 1
Recruiting NCT06066112 - Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body Phase 1
Completed NCT05477810 - Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions Early Phase 1
Completed NCT04546256 - A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Phase 1
Completed NCT05083325 - Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product Phase 1
Completed NCT05061901 - Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions Phase 1
Recruiting NCT04138888 - A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions Phase 1
Completed NCT05145621 - Oral Bio-equivalence Study Phase 1
Completed NCT06124560 - Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions. Phase 1
Completed NCT03340753 - Bioavailability of KBP-5074 Tablet vs Capsule Formulations Phase 1